As 2024 Begins, US FDA’s Novel Agent Prospects Look A Lot Like 2023

 
• By Bridget Silverman
pills in mirror
FDA could see a reflection of its 2023 reviews in this year’s class. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers